Welcome!

News Feed Item

Global Neurotechnology Industry 2014 Report: Company Profiles and Pipeline Analysis from Over 500 Companies and 20 Illnesses

DUBLIN, IRELAND -- (Marketwired) -- 08/15/14 -- Research and Markets (http://www.researchandmarkets.com/research/s7qvsb/the) has announced the addition of a new report "Neurotech Industry 2014 Report" to their offering.

Now in its 10th year, The Neurotechnology Industry 2014 Report is an expanded and updated 650 page report of brain and nervous system markets and treatments. It is the only publication to provide a comprehensive pipeline and market analysis to help investors, companies and entrepreneurs easily identify opportunities, understand the competitive landscape, determine risks and understand the dynamics of rapidly changing CNS markets.

The report includes detailed information on products in development globally for over 20 indications at 800 companies including Alzheimer's, addiction, ALS, anxiety, depressive disorders, epilepsy, migraine, mild cognitive impairment, Huntington's, multiple sclerosis, obesity, pain, Parkinson's, schizophrenia, age-related macular degeneration, sensory disorders, sleep disorders, traumatic brain injury and stroke.

Report Highlights:

--  More than 500 profiles of public and private neurotech companies
    including drugs, devices and diagnostics
--  Pipelines and market analysis for 20 brain and nervous system illnesses
    including: addiction, Alzheimer's disease, anxiety, attention disorders,
    depression, epilepsy, hearing loss, insomnia, mild cognitive impairment,
    migraine, multiple sclerosis, obesity, pain, Parkinson's disease,
    retinal disorders, schizophrenia, stroke, and traumatic brain injury
--  Top neurotech investors, venture capital firms, and venture capital
    trends (1999-Q12014)
--  Neurotech IPOs (2004-Q12014), M&A (2004-Q12014), Partnering and
    Licensing deals (2005-Q12014) and public neurotech stock performance
--  Analysis of biological basis, current treatment options, and emerging
    therapeutic strategies
--  Analysis of compounds, cell therapies and devices in clinical trials
    (and abandoned) by company, mechanism of action and stage of development
    for each indication
--  Global and US market size, worldwide revenues for each indication
--  Extensive discussion of specific technological, demographic, regulatory
    and intellectual property trends

Key Topics Covered:

1: Executive Summary

--  The Brain Industry Revealed
--  Investment Risks and Opportunities

Key Industry Facts and Findings

2: Trends and Drivers

--  Converging Technology Drivers
--  Demographic Drivers
--  Social Drivers
--  Economic Drivers
--  Research Funding
--  Intellectual Property Trends

Neurotech Merger and Acquisition Activity (2005-Q1,2014)

3: Neuropharmaceutical Sector

--  Neuropharmaceutical Sector Overview
--  Neuropharmaceutical Partnering and Licensing
--  Neurology Markets and Pipelines
--  Psychiatry Markets and Pipelines
--  Sensory Markets and Pipelines

4: Stem Cells and Neuroregeneration

--  Defining Stem Cell Markets and Players
--  Stem Cell Approaches
--  Markets and Treatments in Development

5: Neurodevice Sector

--  Neurodevice Sector Overview
--  Neuroprosthetic Devices
--  Neuromodulation Devices
--  Neurosurgical devices
--  Neurosoftware
--  Therapeutic NeuroGaming

6: Neurodiagnostics Sector

--  Neurodiagnostic Sector Overview
--  Neuroimaging Technologies
--  In Vitro Diagnostics
--  Neuroinformatics

7: Private Neurotechnology Investment

--  Venture Capital Investment Trends
--  Neurotech Venture Capital Investment

8: Public Neurotechnology Investment

--  Investing in Public Neurotech Companies
--  Neurotech Initial Public Offerings
--  NeuroInsights Neurotech Index

9: Neurotechnology Research Centers

--  Leading Neurotechnology Research Centers
--  Places to Watch

10: Leading Neurotechnology Regions

--  The Global Neurotech Economy
--  Nexus Ranking and Methodology
--  Established Neurotech Nexus
--  Emerging Neurotech Nexus
--  Nascent Neurotech Nexus
--  Conclusions and Policy Recommendations

11: Company Profiles

--  Neuropharmaceutical & Cell Therapy Companies: Private
--  Neuropharmaceutical & Cell Therapy Companies: Public
--  Neurodevice Companies: Private
--  Neurodevice Companies: Public
--  Neurodiagnostic Companies: Private
--  Neurodiagnostic Companies: Public

12: Index

For more information visit http://www.researchandmarkets.com/research/s7qvsb/the

Source: NeuroInsights

Sector: Pharmaceuticals

Over 400 of the Fortune 500 buy their research from Research and Markets. Some of our clients in the area of Pharmaceuticals include:

--  Pfizer, Inc.
--  Novartis International AG.
--  GlaxoSmithKline plc
--  Merck & Co., Inc.
--  Genentech Inc.
--  McKinsey & Company, Inc.
--  Novo Nordisk
--  IGEN Biotech Group AG
--  Sanofi S.A.
--  Allergan, Inc.
--  FORUM Pharmaceuticals Inc
--  Bio-Rad Laboratories
--  Bain & Company
--  Nestle Health Science
--  Pacira Pharmaceuticals, Inc
--  DBV Technologies SA
--  Chimerix, Inc.

Contacts:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Cloud-based disaster recovery is critical to any production environment and is a high priority for many enterprise organizations today. Nearly 40% of organizations have had to execute their BCDR plan due to a service disruption in the past two years. Zerto on IBM Cloud offer VMware and Microsoft customers simple, automated recovery of on-premise VMware and Microsoft workloads to IBM Cloud data centers.
Why Federal cloud? What is in Federal Clouds and integrations? This session will identify the process and the FedRAMP initiative. But is it sufficient? What is the remedy for keeping abreast of cutting-edge technology? In his session at 21st Cloud Expo, Rasananda Behera will examine the proposed solutions: Private or public or hybrid cloud Responsible governing bodies How can we accomplish?
Today traditional IT approaches leverage well-architected compute/networking domains to control what applications can access what data, and how. DevOps includes rapid application development/deployment leveraging concepts like containerization, third-party sourced applications and databases. Such applications need access to production data for its test and iteration cycles. Data Security? That sounds like a roadblock to DevOps vs. protecting the crown jewels to those in IT.
SYS-CON Events announced today that Cedexis will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Cedexis is the leader in data-driven enterprise global traffic management. Whether optimizing traffic through datacenters, clouds, CDNs, or any combination, Cedexis solutions drive quality and cost-effectiveness.
Elon Musk is among the notable industry figures who worries about the power of AI to destroy rather than help society. Mark Zuckerberg, on the other hand, embraces all that is going on. AI is most powerful when deployed across the vast networks being built for Internets of Things in the manufacturing, transportation and logistics, retail, healthcare, government and other sectors. Is AI transforming IoT for the good or the bad? Do we need to worry about its potential destructive power? Or will we...
The last two years has seen discussions about cloud computing evolve from the public / private / hybrid split to the reality that most enterprises will be creating a complex, multi-cloud strategy. Companies are wary of committing all of their resources to a single cloud, and instead are choosing to spread the risk – and the benefits – of cloud computing across multiple providers and internal infrastructures, as they follow their business needs. Will this approach be successful? How large is the ...
SYS-CON Events announced today that B2Cloud will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. B2Cloud specializes in IoT devices for preventive and predictive maintenance in any kind of equipment retrieving data like Energy consumption, working time, temperature, humidity, pressure, etc.
In his session at @ThingsExpo, Greg Gorman is the Director, IoT Developer Ecosystem, Watson IoT, will provide a short tutorial on Node-RED, a Node.js-based programming tool for wiring together hardware devices, APIs and online services in new and interesting ways. It provides a browser-based editor that makes it easy to wire together flows using a wide range of nodes in the palette that can be deployed to its runtime in a single-click. There is a large library of contributed nodes that help so...
IBM helps FinTechs and financial services companies build and monetize cognitive-enabled financial services apps quickly and at scale. Hosted on IBM Bluemix, IBM’s platform builds in customer insights, regulatory compliance analytics and security to help reduce development time and testing. In his session at 21st Cloud Expo, Lennart Frantzell, a Developer Advocate with IBM, will discuss how these tools simplify the time-consuming tasks of selection, mapping and data integration, allowing devel...
What is the best strategy for selecting the right offshore company for your business? In his session at 21st Cloud Expo, Alan Winters, U.S. Head of Business Development at MobiDev, will discuss the things to look for - positive and negative - in evaluating your options. He will also discuss how to maximize productivity with your offshore developers. Before you start your search, clearly understand your business needs and how that impacts software choices.
SYS-CON Events announced today that SIGMA Corporation will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. uLaser flow inspection device from the Japanese top share to Global Standard! Then, make the best use of data to flip to next page. For more information, visit http://www.sigma-k.co.jp/en/.
SYS-CON Events announced today that NetApp has been named “Bronze Sponsor” of SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. NetApp is the data authority for hybrid cloud. NetApp provides a full range of hybrid cloud data services that simplify management of applications and data across cloud and on-premises environments to accelerate digital transformation. Together with their partners, NetApp em...
Agile has finally jumped the technology shark, expanding outside the software world. Enterprises are now increasingly adopting Agile practices across their organizations in order to successfully navigate the disruptive waters that threaten to drown them. In our quest for establishing change as a core competency in our organizations, this business-centric notion of Agile is an essential component of Agile Digital Transformation. In the years since the publication of the Agile Manifesto, the conn...
There is huge complexity in implementing a successful digital business that requires efficient on-premise and cloud back-end infrastructure, IT and Internet of Things (IoT) data, analytics, Machine Learning, Artificial Intelligence (AI) and Digital Applications. In the data center alone, there are physical and virtual infrastructures, multiple operating systems, multiple applications and new and emerging business and technological paradigms such as cloud computing and XaaS. And then there are pe...
Real IoT production deployments running at scale are collecting sensor data from hundreds / thousands / millions of devices. The goal is to take business-critical actions on the real-time data and find insights from stored datasets. In his session at @ThingsExpo, John Walicki, Watson IoT Developer Advocate at IBM Cloud, will provide a fast-paced developer journey that follows the IoT sensor data from generation, to edge gateway, to edge analytics, to encryption, to the IBM Bluemix cloud, to Wa...